Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Memphasys Ltd ( (AU:MEM) ).
Memphasys Limited has released an updated investor presentation and will host an investor webinar on 8 April 2026, led by Director Marjan Mikel, as part of an expanded investor engagement program. The presentation underpins upcoming meetings and is designed to deepen market understanding of the company’s commercial model and growth trajectory.
The new materials outline Memphasys’ transition from early-stage commercialisation to scaling global revenues, with fresh disclosures on revenue performance across markets and recurring income tied to cartridge usage. They also provide enhanced visibility on unit economics, gross margin potential, operating leverage, and contracted revenue pathways, giving investors clearer insight into the company’s financial profile and scaling strategy.
The most recent analyst rating on (AU:MEM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Memphasys Ltd stock, see the AU:MEM Stock Forecast page.
More about Memphasys Ltd
Memphasys Limited is an Australian-based reproductive biotechnology company focused on assisted human reproduction. Its flagship product, the Felix System, is a patented bioseparation technology that uses electrophoresis and size-exclusion membranes to isolate the most viable sperm cells, aiming to replace traditional centrifugation and become a global standard in sperm preparation for ART procedures.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$12.81M
Learn more about MEM stock on TipRanks’ Stock Analysis page.